Korea Q3 Results Roundup: Lazertinib Boosts Yuhan, Hanmi Dispute Simmers

 
• By Jung Won Shin

Yuhan eyes successors to lazertinib after US approval, leadership dispute at Hanmi drags on and SK Bioscience completes CDMO acquisition.

third quarter
Yuhan Unveils Strategy To Find Next Potential Global Blockbusters (Shutterstock)

More from South Korea

More from Strategy